2021
Surgical Management of Hereditary Breast Cancer
Berger ER, Golshan M. Surgical Management of Hereditary Breast Cancer. Genes 2021, 12: 1371. PMID: 34573353, PMCID: PMC8470490, DOI: 10.3390/genes12091371.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsChemopreventionFemaleGenetic Predisposition to DiseaseGenetic TestingHereditary Breast and Ovarian Cancer SyndromeHeterozygoteHumansMastectomyMutationPractice Guidelines as TopicProphylactic Surgical ProceduresSalpingo-oophorectomyConceptsHereditary breast cancerBreast cancerGenetic variant carriersSurgical risk reductionSurgical management optionsSurgical managementBreast/ovarian cancer susceptibility geneOvarian cancer susceptibility genesVariant carriersCancer susceptibility genesGenetic testingCancer treatmentCancerRisk reductionSusceptibility genesManagement options
2017
Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess).
Golshan M, Loibl S, Huober J, O'Shaughnessy J, Rugo H, Wolmark N, McKee M, Maag D, Sullivan D, Giranda V, Liu X, Von Minckwitz G, Geyer C, Sikov W, Untch M. Breast conservation after neoadjuvant chemotherapy for triple-negative breast cancer: Surgical results from an international randomized trial (BrighTNess). Journal Of Clinical Oncology 2017, 35: 514-514. DOI: 10.1200/jco.2017.35.15_suppl.514.Peer-Reviewed Original ResearchTriple-negative breast cancerNeoadjuvant systemic therapyBreast-conserving therapyBCT ratesBreast cancerSurgical assessmentOperable triple-negative breast cancerGermline BRCA mutation statusHigher mastectomy ratesInternational randomized trialsLarge prospective analysisBRCA mutation statusBCT eligibilityMastectomy ratesNeoadjuvant chemotherapySystemic therapyBreast conservationRandomized trialsSurgical managementSurgical resultsSurgical choicePatient's discretionProspective analysisMutation statusStage II
2015
The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast.
Sagara Y, Barry W, Mallory M, Wong S, Aydogan F, DeSantis S, Golshan M. The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast. Journal Of Clinical Oncology 2015, 33: 1006-1006. DOI: 10.1200/jco.2015.33.15_suppl.1006.Peer-Reviewed Original Research
2010
Can axillary lymph node dissection be omitted in patients with breast cancer and positive sentinel nodes?
Dominici L, Golshan M. Can axillary lymph node dissection be omitted in patients with breast cancer and positive sentinel nodes? Minerva Surgery 2010, 65: 547-54. PMID: 21081866.Peer-Reviewed Original ResearchConceptsBreast cancerSentinel lymphAxillary lymph node dissectionPositive sentinel lymph nodesCompletion axillary dissectionLymph node dissectionPositive axillary nodesPositive sentinel nodesSentinel lymph nodesStandard of careInvasive surgical managementNegative axillaAxillary dissectionAxillary lymphNode dissectionAxillary nodesLymph nodesSentinel nodesSurgical managementSurgical proceduresPatientsLymphCancerDissectionTherapeutic purposes
2003
The effect of ipsilateral whole breast ultrasonography on the surgical management of breast carcinoma
Golshan M, Fung B, Wolfman J, Rademaker A, Morrow M. The effect of ipsilateral whole breast ultrasonography on the surgical management of breast carcinoma. The American Journal Of Surgery 2003, 186: 391-396. PMID: 14553857, DOI: 10.1016/s0002-9610(03)00280-0.Peer-Reviewed Original ResearchConceptsWhole-breast ultrasonographyBreast cancer patientsSurgical managementBreast ultrasonographyCancer patientsBreast cancerHistologic grade 2Percent of patientsBreast conservation therapyHigh-grade lesionsPrimary tumor siteFoci of carcinomaUltrasonography abnormalitiesYounger patientsConservation therapyWide resectionGrade lesionsPhysical examinationAdditional lesionsSignificant abnormalitiesBreast carcinomaPatientsGrade 2UltrasonographyTumor site